• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Heart disease, stroke costs expected to triple by 2030

Heart disease, stroke costs expected to triple by 2030

January 25, 2011 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL — Heart disease, stroke costs expected to triple by 2030. The cost of treating heart disease and stroke is expected to soar to $818 billion over the next two decades in the United States, according to an American Heart Assn. policy statement, writes to HealthDay. The AHA published their report in the Jan. 24 online edition of Circulation.

Healthcare fraud goes international. A $21.7 billion fund backed by celebrities and called an alternative to the bureaucracy of the United Nations sees as much as two-thirds of some grants eaten up by corruption, reports The Associated Press.

Deep brain stimulation could treat high blood pressure. Physicians administering deep brain stimulation to control a man’s severe pain report that they discovered the treatment consistently lowered his tough-to-treat hypertension, reports HealthDay.

Tufts and Harvard Pilgrim plan merger. Massachusetts’ second- and third-largest health plans, Harvard Pilgrim Health Care and Tufts Health Plan, are looking into a merger deal that would reshape the region’s health insurance landscape, writes The Boston Globe.

Obama’s State of the Union address challenge: Talk about healthcare reform – but not too much.

Pitfalls of aging doctors. One-third of physicians are older than 65, the rate of disciplinary actions for older physicians is nearly five times that of younger doctors and there’s a concern there aren’t enoguh safeguards to monitor declining skills as physicians age.

PerkinElmer enters gene sequencing. Via Forbes’ The Medicine Show: “Rather than compete with makers of big DNA sequencing machines, PerkinElmer is creating a service business that will allow researchers to get human genetic data without owning their own DNA sequencers or high-powered supercomputers.”

$4B in healthcare fraud. The federal government said it recovered $4 billion, largely from what it referred to as Medicare fraud.

Viibyrd FDA approval. Clinical Data wins approval for its antidepressant, which includes among its benefits little to no impact on sex drive. The company is already predicting a $1 billion drug.

Good news for Abbott’s RX Acculink. Abbott Laboratories wants its carotid stent approved for a broader array of patients, and indications are the Food & Drug Administration will allow it.

HIMSS swarm. Nearly 30,000 are planning to attend the mega Health IT conference.

Dealflow and more. Cancer vaccine developer Inovio raised $24 million; Pfizer extends a tender offer to King Pharmaceuticals; Nektar Therapeutics raises $220 million; and Amgen buys cancer drugmaker Biovex for $425 million.

Bad news for obesity device industry. McDonalds is raising its prices.

Material from MedCity News was used in this report.

Filed Under: Business/Financial News, News Well Tagged With: American Heart Assn.

More recent news

  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy